12 August 2024

Abingdon Health plc

("Abingdon", the "Group", or the "Company")

Result of General Meeting and Total Voting Rights

Abingdon (AIM:ABDX), a leading international lateral flow contract development and manufacturing organisation, is pleased to announce that, at the General Meeting held earlier today, all resolutions as set out in its Notice of General Meeting dated 24 July 2024 were duly passed.

Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement made at 4:51 p.m. on 24 July 2024, unless the context requires otherwise.

Admission and Total Voting Rights

Following the General Meeting, the Company will allot and issue 53,589,741 Fundraising Shares.

Application has been made to the London Stock Exchange for admission of the Fundraising Shares to trading on AIM. It is expected that Admission will become effective and dealings in the Fundraising Shares will commence on AIM at 8.00 a.m. on or around the 14 August 2024. The Fundraising Shares will rank pari passu in all respects with existing ordinary shares of 2.5 pence each.

Following Admission, the total number of shares in the capital of the Company in issue with voting rights will be 189,523,153 ordinary shares of 2.5 pence each. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Abingdon under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Result of the meeting

Details of the results of the voting (which was undertaken by way of a poll vote) at the General Meeting are set out below. Resolution 1 was proposed and passed as an ordinary resolution and resolution 2 was proposed and passed as a special resolution.

The passing of the Resolutions is one of the conditions to completion of the Fundraising, and as a result of the votes cast in their favour, that particular condition has been satisfied.

For further enquiries:

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon aims to support the increase in need for rapid results across many industries and locations; and produces lateral flow tests in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making and targeted intervention; and can support better outcomes.

Abingdon 's Abingdon Simply Test® range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test® e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test® range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

Founded in 2008, Abingdon is headquartered in York, England.

For more information visit: www.abingdonhealth.com